Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Impact of Udenafil on Exercise Capacity in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients

This study has been completed.
Dong-A PharmTech Co., Ltd.
Information provided by:
Seoul National University Hospital Identifier:
First received: May 31, 2011
Last updated: June 17, 2011
Last verified: May 2011
Pulmonary hypertension (PH) is a serious complication of COPD which is associated with shorter survival, more frequent exacerbation, and increased use of health resources. There is no effective pharmacological treatment for COPD-associated PH. Therefore, the investigators wanted to evaluate the effect of udenafil, a phosphodiesterase- 5 (PDE-5) inhibitor, on exercise capacity of severe COPD patients.

Condition Intervention Phase
Chronic Obstructive Pulmonary Disease
Pulmonary Hypertension
Drug: Udenafil
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The Impact of Udenafil on Exercise Capacity in Severe COPD Patients

Resource links provided by NLM:

Further study details as provided by Seoul National University Hospital:

Primary Outcome Measures:
  • change of 6-minute walk distance [ Time Frame: 8 weeks ]

Secondary Outcome Measures:
  • change of mean pulmonary artery pressure [ Time Frame: 8 weeks ]
    change of lung function, SGRQ score, Borg index, oxygen saturation, mean pulmonary artery pressure

Enrollment: 23
Study Start Date: March 2010
Study Completion Date: May 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Udenafil
Udenafil 50mg qd po
Drug: Udenafil
Udenafil 50mg qd po
Other Name: Zydena

Detailed Description:

Study design

  • prospective, single arm, open-label study
  • Udenafil 50mg qd po for 8 weeks

Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Severe COPD who showed post-bronchodilator forced expiratory volume in 1 second (FEV1) less than 50% of predicted value

Exclusion Criteria:

  • Acute exacerbation within 4 weeks of the study entry
  • Coronary heart disease
  • History of adverse event on PDE-5 inhibitors
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01364181

Korea, Republic of
Seoul National University Bundang Hospital
Seongnam, Gyeonggi-do, Korea, Republic of, 463-707
Sponsors and Collaborators
Seoul National University Hospital
Dong-A PharmTech Co., Ltd.
Principal Investigator: Ho Il Yoon, M.D., Ph.D. Seoul National University Bundang Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Ho Il Yoon, M.D. Ph.D., Seoul National University Hospital Identifier: NCT01364181     History of Changes
Other Study ID Numbers: Udenafil
Study First Received: May 31, 2011
Last Updated: June 17, 2011

Keywords provided by Seoul National University Hospital:
Chronic obstructive pulmonary disease
pulmonary hypertension
Phosphodiesterase 5 inhibitors

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Respiratory Tract Diseases
Respiration Disorders
Signs and Symptoms, Respiratory
Signs and Symptoms
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017